Europe Pharmaceuticals and Healthcare Report Q3 2017
|出版日期||內容資訊||英文 45 Pages
|歐洲的醫藥品、醫療產業 (季度更新報告) Europe Pharmaceuticals and Healthcare Report Q3 2017|
|出版日期: 2017年07月12日||內容資訊: 英文 45 Pages||
本報告提供歐洲各國的製藥產業及醫療產業相關分析，地區整體產業規模的實際成果值、預測值 (過去5年、今後10年份) 估計，產業的課題 (風險) 和未來性的商機 (利潤) 相關評估，域內各地區的詳細趨勢，主要企業簡介等資訊彙整，為您概述為以下內容
BMI View: The outlooks for the emerging and developed European sub-regions are divergent. In Western Europe, cost-containment policies will remain prominent, limiting the growth opportunities from increased demand for chronic disease medicines through ageing populations. In emerging Europe, market growth will be robust, driven by the rapid expansion of healthcare access.
Europe is a region with a high degree of variability of market attractiveness for innovative drugmakers. Western Europe is the home to some of the most attractive pharmaceutical markets globally, however while some markets in emerging Europe represent high growth potential and/or favourable regulatory environments, others will continue to pose significant challenges due to weak patent enforcement or weak purchasing power. It is vital that companies appreciate the varying levels of both investment risk and reward that are present in the markets in Europe. BMI's Innovative Pharmaceuticals Risk/Reward Index tool, which provides a globally comparative and numerically based assessment of a market's attractiveness for companies looking to launch a high-value drug, was established to address this.